Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$38.40 USD

38.40
272,138

-0.09 (-0.23%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $38.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.

Thermo Fisher Rides on End Market Growth, Test Revenues

by Zacks Equity Research

Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.

Veeva Collaborates With RedHill for Coronavirus Clinical Study

by Zacks Equity Research

RedHill has adopted Veeva's (VEEV) Vault CDMS platform for the opaganib study.

Surmodics' Pounce Thrombus Retrieval System Gets FDA Nod

by Zacks Equity Research

The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.

Debanjana Dey headshot

3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic

by Debanjana Dey

Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Veeva CRM to Help Medis Deliver Customized Experience to HCPs

by Zacks Equity Research

Veeva Systems' (VEEV) CRM will be lending Medis teams a flexible solution that adapts to the unique go-to market strategies of every customer.

Here's Why You Should Add NextGen Stock to Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.

AngioDynamics Unveils Auryon Atherectomy System for PAD

by Zacks Equity Research

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

Accuray's Radixact With Synchrony Used in Japan Hospitals

by Zacks Equity Research

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

DexCom Introduces Registry to Monitor Outcomes of G6 System

by Zacks Equity Research

DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.

Here's Why You Should Retain Avanos Medical Stock for Now

by Zacks Equity Research

Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

Why Is SurModics (SRDX) Down 7.3% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OPKO Health's BioReference Laboratories Introduces NGS Assay

by Zacks Equity Research

OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.

Baxter (BAX) Attains FDA De Novo Authorization for Theranova

by Zacks Equity Research

Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.

Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval

by Zacks Equity Research

Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects

Smith+Nephew Unveils Digital Platform to Boost Patient Care

by Zacks Equity Research

With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Here's Why You Should Retain HMS Holdings in Your Portfolio

by Zacks Equity Research

Investor confidence is high on HMS Holdings (HMSY) , thanks to solid prospects.

Thermo Fisher Unveils Suite of Hematology-Oncology Solutions

by Zacks Equity Research

The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from Thermo Fisher's (TMO) new portfolio of hematology-oncology solutions.